290: Batch-to-Batch Variability Is a Design Failure, Not the Norm with Sandra Núñez - Part 2

What if building a world-class biotech company didn’t require owning a single piece of manufacturing equipment or even a lab of your own?

Most startups obsess over bricks, mortar, and stainless steel. Not Sandra Núñez. She’s challenging the status quo as CEO of Amela Biosciences by running a “virtual plant” model: zero in-house production, everything outsourced, and agility baked into every decision. It’s a bold experiment in redefining what a biotech company can look like. One that’s already delivering real, animal-free products to customers today.

Topics discussed:

• Key considerations and pitfalls in tech transfer from academic labs to external CDMO partners (02:34)
• The reasoning behind choosing a virtual plant model with no in-house manufacturing (04:57)
• Criteria for selecting external manufacturing partners, including technical capabilities and cultural fit (06:28)
• Stakeholder communications and managing misconceptions about outsourced manufacturing (07:44)
• Process development challenges when scaling products for commercial use, including impurity profile and scalability of purification methods (08:53)
• Early preparations for future GMP manufacturing and building a foundation for regulatory compliance (11:20)
• The impact of regulatory shifts (like the FDA Modernization Act 2.0) on manufacturing strategy and product reproducibility (12:47)
• Hopes for the company’s future role in the transition to animal-free and regenerative medicine (14:19)
• Practical advice for startup founders considering a leap from corporate biotech to entrepreneurship (15:09)
• Reflections on the importance of addressing batch-to-batch variability and building reproducible systems (16:40)

Smart insight: Don’t accept batch-to-batch variability. Reproducibility is non-negotiable. Batch-to-batch variability, whether in raw materials or process design, is a critical risk that forward-thinking should design out, not accept as inevitable. As Sandra concludes, reproducibility isn’t just a lab problem, it’s a company-building problem, one that shapes strategy, manufacturing partnerships, and regulatory success.

Here are four episodes that pick up the same threads: animal-free matrices, reproducibility by design, and building a biotech without a factory:

• Episodes 271 - 272: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt Baker
• Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito
• Episodes 275 - 276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet
• Episodes 279 - 280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher

Connect with Sandra Núñez:
Website: www.amelabiosciences.com
Company LinkedIn: www.linkedin.com/company/amela-biosciences-ag
Sandra’s LinkedIn: www.linkedin.com/in/sandra-nunez-ch
Sandra’s email: [email protected]

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show